Feasibility Insights In HR+/HER2 - Metastatic Breast Cancer

Clinical trial feasibility demands a data-driven, strategic approach to navigate its inherent complexity. This case study demonstrates how TA Scan’s robust data and advanced analytics streamline feasibility planning for a Phase II clinical trial targeting HR+/HER2- metastatic breast cancer as a second-line treatment. With its advanced content filters, TA Scan enables precise identification of historical trials that match highly specific subpopulation criteria, significantly improving benchmarking accuracy.

The platform’s country analytics deliver rapid insights into regional competition and feasibility, empowering sponsors to make informed decisions on country and site selection. TA Scan further enhances diversity planning by overlaying site experience with demographic, socioeconomic, and ethnic data across 12 countries, facilitating inclusive recruitment strategies. Its Trial Feasibility Flex module combines external data with internal knowledge to model precise, adaptable enrollment timelines and optimize site performance. Overall, TA Scan’s integrated platform transforms feasibility into a predictive, strategic function.